HI
ACRS icon

HBK Investments’s Aclaris Therapeutics ACRS Stock Holding History

HBK Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,867
Closed -$430K – 992
2017
Q2 		$430K Buy
+15,867
New +$431K ﹤0.01% 749

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HBK Investments's ACRS Position: Q3 2017 in Review

HBK Investments sold out of Aclaris Therapeutics (ACRS) in Q3 2017, closing a stake of 15,867 shares — an estimated $430K sold.

HBK Investments first reported a position in ACRS in Q2 2017 and held it in 1 quarter. The position peaked at $430K in Q2 2017. 104 funds tracked by Wall St. Rank hold ACRS as of Q3 2017.

  • HBK Investments reported no remaining Aclaris Therapeutics position as of Q3 2017 after selling out during the quarter.
  • HBK Investments sold 15,867 Aclaris Therapeutics shares in Q3 2017, an estimated $430K.
  • HBK Investments first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 1 quarter.
  • HBK Investments's Aclaris Therapeutics position peaked at $430K in Q2 2017.
  • 104 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2017.

Based on HBK Investments's 13F filing for Q3 2017, filed 14 Nov 2017.